Phathom Pharmaceuticals Operating Expenses Growth & History (PHAT)
Phathom Pharmaceuticals's operating expenses was $312.5M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $312.5M | −$12.2M | −3.77% |
| 2024 | 2024-12-31 | $324.7M | $156.9M | +93.50% |
| 2023 | 2023-12-31 | $167.8M | −$4.6M | −2.68% |
| 2022 | 2022-12-31 | $172.4M | $37.4M | +27.66% |
| 2021 | 2021-12-31 | $135.1M | $9.4M | +7.49% |
| 2020 | 2020-12-31 | $125.7M | $19.4M | +18.31% |
| 2019 | 2019-12-31 | $106.2M | $105.0M | +8570.61% |
| 2018 | 2018-12-31 | $1.2M | — | — |
Phathom Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $63.1M | −$31.2M | −33.10% |
| Q1 2026 | 2026-03-31 | $61.8M | −$41.9M | −40.40% |
| Q4 2025 | 2025-12-31 | $55.9M | −$29.4M | −34.48% |
| Q3 2025 | 2025-09-30 | $58.6M | −$26.2M | −30.91% |
| Q2 2025 | 2025-06-30 | $94.4M | $11.1M | +13.38% |
| Q1 2025 | 2025-03-31 | $103.7M | $32.2M | +45.10% |
| Q4 2024 | 2024-12-31 | $85.3M | $14.9M | +21.13% |
| Q3 2024 | 2024-09-30 | $84.8M | $49.1M | +137.79% |
| Q2 2024 | 2024-06-30 | $83.2M | $51.5M | +162.60% |
| Q1 2024 | 2024-03-31 | $71.4M | $41.4M | +137.52% |
| Q4 2023 | 2023-12-31 | $70.4M | $23.7M | +50.92% |
| Q3 2023 | 2023-09-30 | $35.7M | −$6.9M | −16.15% |
| Q2 2023 | 2023-06-30 | $31.7M | −$13.7M | −30.12% |
| Q1 2023 | 2023-03-31 | $30.1M | −$7.8M | −20.65% |
| Q4 2022 | 2022-12-31 | $46.6M | $13.6M | +41.17% |
| Q3 2022 | 2022-09-30 | $42.5M | $9.4M | +28.34% |
| Q2 2022 | 2022-06-30 | $45.4M | $10.0M | +28.44% |
| Q1 2022 | 2022-03-31 | $37.9M | $4.3M | +12.87% |
| Q4 2021 | 2021-12-31 | $33.0M | −$19.4M | −36.99% |
| Q3 2021 | 2021-09-30 | $33.1M | $307,000 | +0.94% |
| Q2 2021 | 2021-06-30 | $35.3M | $15.3M | +76.41% |
| Q1 2021 | 2021-03-31 | $33.6M | $13.2M | +64.83% |
| Q4 2020 | 2020-12-31 | $52.4M | $36.7M | +234.16% |
| Q3 2020 | 2020-09-30 | $32.8M | $26.5M | +422.60% |
| Q2 2020 | 2020-06-30 | $20.0M | −$63.0M | −75.88% |
| Q1 2020 | 2020-03-31 | $20.4M | $19.1M | +1561.91% |
| Q4 2019 | 2019-12-31 | $15.7M | $15.2M | +3379.60% |
| Q3 2019 | 2019-09-30 | $6.3M | $6.0M | +2244.03% |
| Q2 2019 | 2019-06-30 | $83.0M | $82.8M | +32454.51% |
| Q1 2019 | 2019-03-31 | $1.2M | $975,000 | +388.45% |
| Q4 2018 | 2018-12-31 | $451,000 | — | — |
| Q3 2018 | 2018-09-30 | $268,000 | — | — |
| Q2 2018 | 2018-06-30 | $255,000 | — | — |
| Q1 2018 | 2018-03-31 | $251,000 | — | — |
Phathom Pharmaceuticals operating expenses trends
Over the last five fiscal years, Phathom Pharmaceuticals's operating expenses increased from $125.7M to $312.5M, a change of $186.8M. The latest reported quarter, Q2 2026, shows $63.1M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗